<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461758</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0813</org_study_id>
    <secondary_id>Influenza in IBD</secondary_id>
    <nct_id>NCT02461758</nct_id>
  </id_info>
  <brief_title>Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients</brief_title>
  <official_title>Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal
      tract which includes Crohn's disease (CD) and ulcerative colitis (UC). A recent
      epidemiological investigation estimates that nearly 4 million people worldwide are affected
      and approximately 1.4 million of these cases occur in the United States. IBD can lead to
      debilitating symptoms, hospitalizations, decreased quality of life, frequent procedures
      and/or surgery. Treatment options consist of immunosuppressive therapy, such as systemic
      corticosteroids, immunomodulators (thiopurines and methotrexate) and/or biologics, such as
      tumor necrosis factor alpha (TNF) agents or an integrin inhibitor, vedolizumab. They can
      achieve clinical remission and decrease the risk of complications, but also increase the risk
      for opportunistic infections, including influenza.

      Multiple studies have shown lower influenza vaccine responses in patients with IBD compared
      to healthy individuals; IBD patients treated with TNF agents or combination therapy (TNF
      inhibitors and immunomodulators) are very likely to mount a poor immune response. Influenza
      serum antibody concentration correlates with protection from infection following vaccination.
      Therefore, increasing influenza antibody responses in patients with IBD would appear to be
      critical to improving protection from influenza. A high dose (HD) influenza vaccine
      containing four times more hemagglutinin was licensed based on its ability to induce higher
      antibody concentrations compared to standard dose (SD) in adults 65 years or older.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure Antibody Concentrations in Immunosuppressed IBD Patients Who Receive High Dose and Standard of Care Dose Influenza Vaccine</measure>
    <time_frame>Pre-immunization and 2-4 weeks post immunization</time_frame>
    <description>Influenza vaccine antibody concentration will be measured in immunosuppressed IBD patients who receive high dose and standard of care dose influenza vaccine.
Higher antibody concentrations are associated with better protection from infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate Against Influenza Vaccine in Patients With Inflammatory Bowel Disease: Number of Participants Positive for Seroconversion</measure>
    <time_frame>4 weeks</time_frame>
    <description>Vaccine response rates for influenza vaccines in patients with inflammatory bowel disease will be accessed by number of patients who has shown significant seroconversion. Seroconversion is defined as a four fold increase in antibody concentration from preimmunization to 4 weeks post immunization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection: Number of Participants With Antibody Concentration at Least 1:40 at Week 4 Postimmunization</measure>
    <time_frame>4 weeks</time_frame>
    <description>Seroprotection is defined as an antibody concentration of at least 1:40 at 4 weeks post-immunization which confers protection from infection in about 50% of individuals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection: Number of Participants With Antibody Titer of 160 at Week 4 Post-immunization</measure>
    <time_frame>4 weeks</time_frame>
    <description>Seroprotection is defined by the FDA as post-immunization concentration of 1:160 that confers protection from infection to 95% of the population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure Antibody Concentrations in Immunosuppressed IBD Patients Who Receive High Dose and Standard of Care Dose Influenza Vaccine</measure>
    <time_frame>6 months post-immunization</time_frame>
    <description>Influenza vaccine antibody concentration will be measured in immunosuppressed IBD patients who receive high dose and standard of care dose influenza vaccine.
Higher antibody concentrations are associated with better protection from infection.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Inflammatory Bowel Disease (IBD)</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A group of 20 healthy individuals without IBD, other chronic diseases, or immunosuppressive therapy will be enrolled. All healthy individuals will receive standard dose influenza vaccine SDIV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vedolizumab Group + standard dose influenza vaccine (SDIV)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A group of 20 patients who are currently on vedolizumab. All individuals in this group will receive SDIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose influenza vaccine (HDIV)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This arm will be a double blind randomized controlled trial of High dose influenza vaccine (HDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose influenza vaccine (SDIV)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This arm will be a double blind randomized controlled trial of standard dose influenza vaccine (SDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard dose Influenza vaccine (SDIV)</intervention_name>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Standard dose influenza vaccine (SDIV)</arm_group_label>
    <arm_group_label>Vedolizumab Group + standard dose influenza vaccine (SDIV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dose influenza vaccine (HDIV)</intervention_name>
    <arm_group_label>High dose influenza vaccine (HDIV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        CASES Specific Aim #1 Inclusion Criteria

          -  A history of chronic (greater than 3 month) ulcerative colitis or Crohn's disease
             diagnosed and documented by the standard clinical, radiographic, endoscopic and
             histopathologic criteria.

          -  Ages 18-64

          -  Currently taking anti-TNF therapy (infliximab, golilumab, adalimumab, or certolizumab)
             for at least 3 months

          -  Exclusion Criteria

          -  Received season's influenza vaccine

          -  Allergy to eggs or influenza vaccine

          -  Currently use of systemic steroids in the past 3 months

        Specific Aim #2 Inclusion criteria

          -  A history of chronic (greater than 3 month) ulcerative colitis or Crohn's disease
             diagnosed and documented by the standard clinical, radiographic, endoscopic and
             histopathologic criteria.

          -  Ages 18-64

          -  Currently on vedolizumab therapy

        Exclusion Criteria

          -  Received season's influenza vaccine

          -  Allergy to eggs or influenza vaccine

          -  Currently use of systemic steroids in the past 3 months

        Control group Inclusion criteria

          -  Age 18-64

          -  Willing to participate in study

        Control group Exclusion criteria

          -  Currently on immunosuppressive therapy

          -  Has a chronic health condition that may have an impact on vaccine antibody
             concentrations as deemed by the investigators, including chronic liver disease, celiac
             disease, history of solid organ or bone marrow transplantation.

          -  Older than age 65 years

          -  Unconfirmed Measles, Mumps, and Rubella (MMR) vaccination status

          -  Patients in whom venipuncture are not feasible due to poor tolerability or lack of
             easy access.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Freddy Caldera</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin School of Medicine and Public Health, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Hospital &amp; Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Caldera F, Hillman L, Saha S, Wald A, Grimes I, Zhang Y, Sharpe AR, Reichelderfer M, Hayney MS. Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial. Inflamm Bowel Dis. 2020 Mar 4;26(4):593-602. doi: 10.1093/ibd/izz164.</citation>
    <PMID>31504526</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 26, 2015</study_first_submitted>
  <study_first_submitted_qc>May 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <results_first_submitted>June 26, 2019</results_first_submitted>
  <results_first_submitted_qc>September 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2019</results_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT02461758/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 13, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT02461758/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>A group of 20 healthy individuals without IBD, other chronic diseases, or immunosuppressive therapy will be enrolled. All healthy individuals will receive standard dose influenza vaccine SDIV.</description>
        </group>
        <group group_id="P2">
          <title>Vedolizumab Group</title>
          <description>A group of 20 patients who are currently on vedolizumab. All individuals in this group will receive SDIV</description>
        </group>
        <group group_id="P3">
          <title>High Dose Influenza Vaccine (HDIV)</title>
          <description>This arm will be a double blind randomized controlled trial of High dose influenza vaccine (HDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.</description>
        </group>
        <group group_id="P4">
          <title>Standard Dose Influenza Vaccine (SDIV)</title>
          <description>This arm will be a double blind randomized controlled trial of standard dose influenza vaccine (SDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>A group of 20 healthy individuals without IBD, other chronic diseases, or immunosuppressive therapy will be enrolled. All healthy individuals will receive standard dose influenza vaccine SDIV.</description>
        </group>
        <group group_id="B2">
          <title>Vedolizumab Group</title>
          <description>A group of 20 patients who are currently on vedolizumab. All individuals in this group will receive SDIV</description>
        </group>
        <group group_id="B3">
          <title>High Dose Influenza Vaccine (HDIV)</title>
          <description>This arm will be a double blind randomized controlled trial of high dose influenza vaccine (HDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.</description>
        </group>
        <group group_id="B4">
          <title>Standard Dose Influenza Vaccine (SDIV)</title>
          <description>This arm will be a double blind randomized controlled trial of standard dose influenza vaccine (SDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="15"/>
            <count group_id="B5" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.35" spread="9.89"/>
                    <measurement group_id="B2" value="36.57" spread="16.16"/>
                    <measurement group_id="B3" value="34.96" spread="12.92"/>
                    <measurement group_id="B4" value="39.35" spread="11.98"/>
                    <measurement group_id="B5" value="37.81" spread="12.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measure Antibody Concentrations in Immunosuppressed IBD Patients Who Receive High Dose and Standard of Care Dose Influenza Vaccine</title>
        <description>Influenza vaccine antibody concentration will be measured in immunosuppressed IBD patients who receive high dose and standard of care dose influenza vaccine.
Higher antibody concentrations are associated with better protection from infection.</description>
        <time_frame>Pre-immunization and 2-4 weeks post immunization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose of Influenza Vaccine (HDIV) Group</title>
            <description>This arm will be a double blind randomized controlled trial of high dose influenza vaccine (HDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Influenza Vaccine (SDIV) Group</title>
            <description>This arm will be a double blind randomized controlled trial of standard dose influenza vaccine (SDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.</description>
          </group>
          <group group_id="O3">
            <title>Vedolizumab Group</title>
            <description>A group of 20 patients who are currently on vedolizumab. All individuals in this group will receive SDIV</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>A group of 20 healthy individuals without IBD, other chronic diseases, or immunosuppressive therapy will be enrolled. All healthy individuals will receive standard dose influenza vaccine SDIV.</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Antibody Concentrations in Immunosuppressed IBD Patients Who Receive High Dose and Standard of Care Dose Influenza Vaccine</title>
          <description>Influenza vaccine antibody concentration will be measured in immunosuppressed IBD patients who receive high dose and standard of care dose influenza vaccine.
Higher antibody concentrations are associated with better protection from infection.</description>
          <units>Antibody Titer</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Influenza A H1N1, pre-immunization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160" lower_limit="80" upper_limit="240"/>
                    <measurement group_id="O2" value="160" lower_limit="80" upper_limit="160"/>
                    <measurement group_id="O3" value="160" lower_limit="80" upper_limit="320"/>
                    <measurement group_id="O4" value="160" lower_limit="80" upper_limit="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A H1N1, 2-4 weeks post immunization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320" lower_limit="150" upper_limit="320"/>
                    <measurement group_id="O2" value="160" lower_limit="80" upper_limit="320"/>
                    <measurement group_id="O3" value="320" lower_limit="160" upper_limit="640"/>
                    <measurement group_id="O4" value="320" lower_limit="160" upper_limit="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A H3N2, Pre-immunization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="40" upper_limit="160"/>
                    <measurement group_id="O2" value="40" lower_limit="20" upper_limit="40"/>
                    <measurement group_id="O3" value="80" lower_limit="80" upper_limit="160"/>
                    <measurement group_id="O4" value="80" lower_limit="40" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A H3N2, 2-4 weeks post immunization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160" lower_limit="80" upper_limit="320"/>
                    <measurement group_id="O2" value="80" lower_limit="40" upper_limit="160"/>
                    <measurement group_id="O3" value="320" lower_limit="160" upper_limit="320"/>
                    <measurement group_id="O4" value="160" lower_limit="160" upper_limit="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B Victoria,Pre-immunization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O2" value="10" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O3" value="20" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O4" value="20" lower_limit="20" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B Victoria, 2-4 weeks post immunization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="15" upper_limit="20"/>
                    <measurement group_id="O2" value="20" lower_limit="20" upper_limit="40"/>
                    <measurement group_id="O3" value="20" lower_limit="20" upper_limit="40"/>
                    <measurement group_id="O4" value="20" lower_limit="20" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B Yamagata, Pre-immunization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O2" value="10" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O3" value="20" lower_limit="10" upper_limit="40"/>
                    <measurement group_id="O4" value="20" lower_limit="10" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B Yamagata, 2-4 weeks post immunization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O2" value="20" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O3" value="40" lower_limit="20" upper_limit="40"/>
                    <measurement group_id="O4" value="20" lower_limit="13" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate Against Influenza Vaccine in Patients With Inflammatory Bowel Disease: Number of Participants Positive for Seroconversion</title>
        <description>Vaccine response rates for influenza vaccines in patients with inflammatory bowel disease will be accessed by number of patients who has shown significant seroconversion. Seroconversion is defined as a four fold increase in antibody concentration from preimmunization to 4 weeks post immunization.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Influenza Vaccine (SDIV) Group</title>
            <description>This arm will be a double blind randomized controlled trial of standard dose influenza vaccine (SDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.</description>
          </group>
          <group group_id="O2">
            <title>High Dose of Influenza Vaccine(HDIV) Group</title>
            <description>This arm will be a double blind randomized controlled trial of high dose influenza vaccine (HDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.</description>
          </group>
          <group group_id="O3">
            <title>Vedolizumab Group</title>
            <description>A group of 20 patients who are currently on vedolizumab. All individuals in this group will receive SDIV</description>
          </group>
          <group group_id="O4">
            <title>Contorl Group</title>
            <description>A group of 20 healthy individuals without IBD, other chronic diseases, or immunosuppressive therapy will be enrolled. All healthy individuals will receive standard dose influenza vaccine SDIV.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate Against Influenza Vaccine in Patients With Inflammatory Bowel Disease: Number of Participants Positive for Seroconversion</title>
          <description>Vaccine response rates for influenza vaccines in patients with inflammatory bowel disease will be accessed by number of patients who has shown significant seroconversion. Seroconversion is defined as a four fold increase in antibody concentration from preimmunization to 4 weeks post immunization.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Influenza A H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one virus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least two viruses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three viruses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection: Number of Participants With Antibody Concentration at Least 1:40 at Week 4 Postimmunization</title>
        <description>Seroprotection is defined as an antibody concentration of at least 1:40 at 4 weeks post-immunization which confers protection from infection in about 50% of individuals</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Influenza Vaccine (SDIV) Group</title>
            <description>This arm will be a double blind randomized controlled trial of standard dose influenza vaccine (SDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.
.</description>
          </group>
          <group group_id="O2">
            <title>High Dose of Influenza Vaccine(HDIV) Group</title>
            <description>This arm will be a double blind randomized controlled trial of high dose influenza vaccine (HDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.</description>
          </group>
          <group group_id="O3">
            <title>Vedolizumab Group</title>
            <description>A group of 20 patients who are currently on Vedolizumab. All individuals in this group will receive SDIV</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>A group of 20 healthy individuals without IBD, other chronic diseases, or immunosuppressive therapy will be enrolled. All healthy individuals will receive standard dose influenza vaccine SDIV.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection: Number of Participants With Antibody Concentration at Least 1:40 at Week 4 Postimmunization</title>
          <description>Seroprotection is defined as an antibody concentration of at least 1:40 at 4 weeks post-immunization which confers protection from infection in about 50% of individuals</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Influenza A H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one virus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least two virus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three viruses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection: Number of Participants With Antibody Titer of 160 at Week 4 Post-immunization</title>
        <description>Seroprotection is defined by the FDA as post-immunization concentration of 1:160 that confers protection from infection to 95% of the population.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Influenza Vaccine (SDIV) Group</title>
            <description>This arm will be a double blind randomized controlled trial of standard dose influenza vaccine (SDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.
.</description>
          </group>
          <group group_id="O2">
            <title>High Dose of Influenza Vaccine(HDIV) Group</title>
            <description>This arm will be a double blind randomized controlled trial of high dose influenza vaccine (HDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.</description>
          </group>
          <group group_id="O3">
            <title>Vedolizumab Group</title>
            <description>A group of 20 patients who are currently on Vedolizumab. All individuals in this group will receive SDIV</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>A group of 20 healthy individuals without IBD, other chronic diseases, or immunosuppressive therapy will be enrolled. All healthy individuals will receive standard dose influenza vaccine SDIV.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection: Number of Participants With Antibody Titer of 160 at Week 4 Post-immunization</title>
          <description>Seroprotection is defined by the FDA as post-immunization concentration of 1:160 that confers protection from infection to 95% of the population.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Influenza A H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one virus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least two virus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three viruses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Antibody Concentrations in Immunosuppressed IBD Patients Who Receive High Dose and Standard of Care Dose Influenza Vaccine</title>
        <description>Influenza vaccine antibody concentration will be measured in immunosuppressed IBD patients who receive high dose and standard of care dose influenza vaccine.
Higher antibody concentrations are associated with better protection from infection.</description>
        <time_frame>6 months post-immunization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose of Influenza Vaccine (HDIV) Group</title>
            <description>This arm will be a double blind randomized controlled trial of high dose influenza vaccine (HDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Influenza Vaccine (SDIV) Group</title>
            <description>This arm will be a double blind randomized controlled trial of standard dose influenza vaccine (SDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.</description>
          </group>
          <group group_id="O3">
            <title>Vedolizumab Group</title>
            <description>A group of 20 patients who are currently on vedolizumab. All individuals in this group will receive SDIV</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>A group of 20 healthy individuals without IBD, other chronic diseases, or immunosuppressive therapy will be enrolled. All healthy individuals will receive standard dose influenza vaccine SDIV.</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Antibody Concentrations in Immunosuppressed IBD Patients Who Receive High Dose and Standard of Care Dose Influenza Vaccine</title>
          <description>Influenza vaccine antibody concentration will be measured in immunosuppressed IBD patients who receive high dose and standard of care dose influenza vaccine.
Higher antibody concentrations are associated with better protection from infection.</description>
          <units>Antibody Titer</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Influenza A H1N1, 6 months post immunization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160" lower_limit="80" upper_limit="320"/>
                    <measurement group_id="O2" value="160" lower_limit="80" upper_limit="320"/>
                    <measurement group_id="O3" value="160" lower_limit="160" upper_limit="320"/>
                    <measurement group_id="O4" value="160" lower_limit="80" upper_limit="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A H3N2, 6 months post immunization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="40" upper_limit="80"/>
                    <measurement group_id="O2" value="80" lower_limit="40" upper_limit="160"/>
                    <measurement group_id="O3" value="160" lower_limit="80" upper_limit="160"/>
                    <measurement group_id="O4" value="80" lower_limit="80" upper_limit="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B Victoria, 6 months post immunization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O2" value="20" lower_limit="18" upper_limit="40"/>
                    <measurement group_id="O3" value="40" lower_limit="20" upper_limit="40"/>
                    <measurement group_id="O4" value="20" lower_limit="20" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B Yamagata, 6 months post immunization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O2" value="20" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O3" value="20" lower_limit="20" upper_limit="40"/>
                    <measurement group_id="O4" value="20" lower_limit="20" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 7 days</time_frame>
      <desc>AEs were recorded after administration of the vaccine from days 0-6 using the adverse event dairy. Adverse event data is reported for 24 participants in the HDIV arm as 1 participant did not submit the diary card for adverse event reporting. Adverse event are reported just for anti-TNF monotherapy group HDIV and SDIV since these were the primary outcome.No AEs were collected for vedolizumab group and control group as they were secondary outcomes which were dependent on primary outcomes.</desc>
      <group_list>
        <group group_id="E1">
          <title>High Dose Influenza Vaccine (HDIV)</title>
          <description>This arm will be a double blind randomized controlled trial of High dose influenza vaccine (HDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.</description>
        </group>
        <group group_id="E2">
          <title>Standard Dose Influenza Vaccine (SDIV)</title>
          <description>This arm will be a double blind randomized controlled trial of standard dose influenza vaccine (SDIV) for IBD patients on TNF monotherapy.
40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Muscle Aches</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="24"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Local reactions: Pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Local reaction: Redness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>FREDDY CALDERA, ASST PROFESSOR , GASTROENTEROLOGY</name_or_title>
      <organization>University of Wisconsin School of Medicine and Public Health</organization>
      <phone>(608) 263-1995</phone>
      <email>fcaldera@medicine.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

